AACTG recommendations for metabolic problems. Guide covers insulin resistance and diabetes.
The Adult AIDS Clinical Trials Group has responded to research showing a link between HIV antiretroviral treatment and metabolic disorders with guidelines that offer recommendations for assessing, monitoring, and treating the problem. According to the AACTG, up to 40% of HIV patients on a protease inhibitor-containing regimen will have impaired glucose tolerance caused by significant insulin resistance, which can lead to increased risk of cardiovascular complication.
D001786:Blood Glucose / Q000032:analysis; D003920:Diabetes Mellitus / Q000139:chemically induced*; D004032:Diet; D005951:Glucose Tolerance Test; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006801:Humans; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D017410:Practice Guidelines as Topic; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*
D001786:Blood Glucose; D017320:HIV Protease Inhibitors; D008055:Lipids; D018894:Reverse Transcriptase Inhibitors